Ocular Therapeutix (NSDQ:OCUL) touted interim data today from its phase III trial of Dextenza for the treatment of post-surgical ocular inflammation and pain. The bioresorbable intracanalicular hydrogel plug is designed to release drugs at the ocular surface for up to 30 days. The company announced last month that Dextenza met the trial’s 2 primary efficacy endpoints: […]
Augmenix touts long-term data for hydrogel spacer in prostate cancer patients
Augmenix Inc. said today that long-term outcomes data from the company’s phase III clinical trial evaluating its hydrogel spacer, SpaceOAR, were published in the International Journal of Radiation Oncology Biology and Physics. The spacer is designed to separate the rectum and prostate during prostate cancer radiotherapy, according to the Waltham, Mass.-based company. The newly published data were […]
Researchers stunt growth of ovarian cancer with nanohydrogels
Researchers at the Georgia Institute of Technology have developed a targeted therapy using nanohydrogels to stunt the growth of ovarian tumors in in vivo tests in mice, according to a new study. The nanohydrogel is a gel pellet that researchers can load with RNA to carry into cancer cells and knock down a particular protein. “The dramatic […]
Flamel Technologies tops Q3 revenue, EPS estimate
Shares in Flamel Technologies (NSDQ:FLML) rose today after the pharmaceutical company met expectations on Wall Street with its 3rd quarter results. The Venissieux, France-based company posted a loss of -$22.3 million on sales of $32.1 million for the 3 months ended Sept. 30, for bottom-line growth of 20% despite a sales loss of 32% compared with the […]
Encapsulating single cells in tunable hydrogel could boost cell therapies
Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Harvard John A. Paulson School of Engineering and Applied Sciences have developed a microfluidic approach to trap individual cells within a hydrogel material that can be tuned to match the physiological conditions of the body, according to a study published this […]
Ocular Therapeutix inks $315 deal with Regeneron
Ocular Therapeutix (NSDQ:OCUL) said today that it landed a licensing deal with Regeneron (NSDQ:REGN) to develop a sustained-release version of Regeneron’s aflibercept (Eylea), a therapy for wet age-related macular degeneration. The deal will cost Regeneron $10 million up front, and in total could cost the Tarrytown, N.Y.-based biotech $315 million if regulatory and commercialization milestones are met. The terms […]
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn